KZR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.570

Open

6.570

VWAP

6.49

Vol

10.32K

Mkt Cap

46.94M

Low

6.405

Amount

66.99K

EV/EBITDA(TTM)

--

Total Shares

7.32M

EV

-36.62M

EV/OCF(TTM)

--

P/S(TTM)

--

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

Show More

Events Timeline

(ET)

2026-01-09

06:10:00

Kezar Life Sciences Granted FDA Type C Meeting to Discuss New Drug Development

2025-12-10 (ET)

2025-12-10

08:20:00

Kazia Therapeutics Releases New Data on Paxalisib for Breast Cancer

2025-12-02 (ET)

2025-12-02

09:40:00

Kazia Therapeutics Trading Halted Due to Volatility Trading Pause

2025-11-12 (ET)

2025-11-12

16:04:40

Kezar Life Sciences Announces Q3 EPS of $1.53, Below Consensus Estimate of $1.96

2025-10-16 (ET)

2025-10-16

16:07:19

Kezar Life Sciences to consider strategic options

2025-10-16

16:06:41

Kezar warns that FDA-mandated interim study could postpone upcoming zetomipzomib trials.

2025-08-13 (ET)

2025-08-13

16:02:11

Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)

News

moomoo

Revised: ENODIA THERAPEUTICS - KEZAR TO RECEIVE $1 MILLION UPFRONT AND POTENTIAL MILESTONE PAYMENTS OF UP TO $127 MILLION (CORRECTS OMITTED WORD 'KEZAR')

NASDAQ.COM

01-09NASDAQ.COM

KZR Secures FDA Type C Meeting to Discuss Zetomipzomib Development

Benzinga

2025-10-17Benzinga

Jefferies Lowers Kezar Life Sciences Rating to Hold and Reduces Price Target to $7

Benzinga

2025-10-17Benzinga

Kezar Initiates Strategic Review Following FDA Setback on Liver Drug Development

NASDAQ.COM

2025-09-17NASDAQ.COM

Everything You Should Know About the Upgrade to Buy for Kezar Life Sciences (KZR)

Benzinga

2025-07-16Benzinga

FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study

3 Analyst Rating

Wall Street analysts forecast KZR stock price to rise

0 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

Jefferies

Maury Raycroft

Buy -> Hold

downgrade

$18 -> $7

AI Analysis

2025-10-17

Reason

Jefferies

Maury Raycroft

Price Target

$18 -> $7

AI Analysis

2025-10-17

downgrade

Buy -> Hold

Reason

Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to Hold from Buy with a price target of $7, down from $18. The company announced it could not align with the FDA on a registrational path for zetomipzomib in autoimmune hepatitis, leading to a formal process to explore strategic alternatives, the analyst tells investors in a research note. The firm lowered the probability of sucess of zetomipzomib to 10% from 25% and downgraded the shares.

William Blair

Matthew Phipps

Outperform -> Market Perform

downgrade

2025-10-17

Reason

William Blair

Matthew Phipps

Price Target

2025-10-17

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to Market Perform from Outperform without a price target. The company announced it has been unable to align with the FDA on a registrational trial for zetomipzomib in autoimmune hepatitis and is initiating a process to explore strategic alternatives, the analyst tells investors in a research note. The firm is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KZR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Kezar Life Sciences Inc (KZR.O) is -1.24, compared to its 5-year average forward P/E of -3.66. For a more detailed relative valuation and DCF analysis to assess Kezar Life Sciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.66

Current PE

-1.24

Overvalued PE

0.19

Undervalued PE

-7.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

8.65

Current PS

0.00

Overvalued PS

24.72

Undervalued PS

-7.43

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

find sideways stocks for iron condor short

Intellectia · 32 candidates

Rsi Category: moderateBeta: LowRisk, ModerateRiskMonth Price Change Pct: $-3.00 - $3.00Is Optionable: TrueOption Iv Rank: 40 - 80

Ticker

Name

Market Cap$

T-Mobile US Inc

220.78B

Abeona Therapeutics Inc

280.98M

Theravance Biopharma Inc

1.01B

Vertex Pharmaceuticals Inc

118.96B

Best Buy Co Inc

14.09B

Ross Stores Inc

62.42B

Whales Holding KZR

Qiming Weichuang Venture Capital Management (Shanghai) Company Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kezar Life Sciences Inc (KZR) stock price today?

The current price of KZR is 6.49 USD — it has increased 1.25

What is Kezar Life Sciences Inc (KZR)'s business?

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

What is the price predicton of KZR Stock?

Wall Street analysts forecast KZR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZR is6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Kezar Life Sciences Inc (KZR)'s revenue for the last quarter?

Kezar Life Sciences Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Kezar Life Sciences Inc (KZR)'s earnings per share (EPS) for the last quarter?

Kezar Life Sciences Inc. EPS for the last quarter amounts to -1.53 USD, decreased -94.50

How many employees does Kezar Life Sciences Inc (KZR). have?

Kezar Life Sciences Inc (KZR) has 55 emplpoyees as of March 25 2026.

What is Kezar Life Sciences Inc (KZR) market cap?

Today KZR has the market capitalization of 46.94M USD.